NEWS

Aruvant Appoints Joseph McIntosh, M.D. as Chief Medical Officer

Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell disease administered with reduced intensity conditioning Most recently as head of clinical...

Aruvant Appoints William Chou as Chief Executive Officer

Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia Chou previously led the development and approval of Kymriah® for diffuse large B-cell lymphoma He...